If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
The win Restorbio is claiming in a mid-stage study is by no means clear-cut.
Nine IPOs have got away so far this year, and one of them is very big indeed.